EUVIMEDEUVIMED entdecken
Multizentrische StudieOpen Access · CC BY-NC-ND 4.0

Pre-Admission Beta-Blocker Therapy and Outcomes in Cardiogenic Shock: Insights from the Altshock-2 Registry

Matteo Pagnesi iD, Mauro Riccardi, Alice Sacco, Giovanni Tavecchia, Giovanna Viola, Simone Frea, Martina Briani, Letizia Fausta Bertoldi, Maurizio Bertaina, Luciano Potena, Serafina Valente, Marco Marini und 10 weitere

ESC Heart Failure · 2025

DOI: 10.1002/ehf2.15322 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift ESC Heart Failure, 2025. Verfasst von Matteo Pagnesi und 21 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Cardiology, Department of Medical and Surgical Specialties, Radiological Sciences and Public Health, University of Brescia, Spedali Civi…. Hauptthemen laut MEDLINE: Shock, Cardiogenic, Registries, Adrenergic beta-Antagonists. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 24 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aims

We aimed to assess the impact of pre-admission beta-blocker (BB) therapy on the clinical characteristics, in-hospital treatment and outcomes of patients with cardiogenic shock (CS).

Methods

All patients enrolled in the multicentre prospective Altshock-2 registry since March 2020 with available data on pre-admission BB therapy were included. Clinical characteristics, in-hospital management, haemodynamic parameters and clinical outcomes were compared in patients with versus without BB therapy. The primary endpoint was in-hospital mortality.

Results

A total of 668 patients were included [median age 66 (56–74) years, male sex 76.5%]: 299 patients (44.8%) with and 369 patients (55.2%) without previous BB therapy. Patients receiving pre-admission BB therapy had more frequently heart failure-related CS (43.8% vs. 17.9%) and less frequently cardiac arrest at presentation (20.1% vs. 27.8%, P = 0.027). Levosimendan was used less frequently and dobutamine was used more frequently in patients with baseline BB therapy (P = 0.033 and P = 0.043, respectively). Differences in the early haemodynamic response to vasoactive drugs were observed between patients with and without previous BB therapy, with a significant impact of baseline BB on mean arterial pressure (MAP) response during norepinephrine infusion (P = 0.012) and with dobutamine having a reduced response in MAP and heart rate in patients receiving BBs before admission (P = 0.023 and P = 0.001, respectively). In-hospital mortality was not significantly different between the BB and no-BB groups (40% vs. 33.7%; adjusted odds ratio 1.32, 95% confidence interval 0.84–2.07, P = 0.224). Similarly, baseline BB therapy was not independently associated with 48 h mortality (12.7% vs. 14.6%; adjusted odds ratio 1.09, 95% confidence interval 0.64–1.87, P = 0.749). The lack of association between baseline BB therapy and mortality was also confirmed at inverse probability of treatment weighting-adjusted analysis.

Conclusions

In a real-world, contemporary cohort of patients with CS, previous BB therapy influenced the haemodynamic response to vasoactive drugs, but it was not associated with in-hospital mortality.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Shock, CardiogenicRegistriesAdrenergic beta-AntagonistsHumansMaleFemaleAgedMiddle AgedHospital MortalityProspective StudiesTreatment OutcomeHemodynamicsFollow-Up StudiesSurvival Rate

Stichwörter der Autor:innen

Cardiogenic shockbeta‐blockersinotropesmortalityvasopressors

Substanzen

Adrenergic beta-Antagonists

Autor:innen und Institutionen

  • Institute of Cardiology, Department of Medical and Surgical Specialties, Radiological Sciences and Public Health, University of Brescia, Spedali Civili di Brescia, Brescia, Italy.
  • Cardiac Intensive Care Unit, 'De Gasperis' Cardio Center, ASST Grande Ospedale Metropolitano Niguarda, Milan, Italy.
  • Cardiac Intensive Care Unit, Città della Salute e della Scienza di Torino, Torino, Italy.
  • Humanitas Research Hospital IRCCS Rozzano, Milan, Italy.
  • Division of Cardiology, San Giovanni Bosco Hospital, ASL Città di Torino, Torino, Italy.
  • Cardiology Unit, Cardio-Thoraco-Vascular Department, University Hospital of Bologna, Policlinico S. Orsola-Malpighi, Bologna, Italy.

ORCID-Profile: Matteo Pagnesi

Zitieren

APA

Pagnesi, M., Riccardi, M., Sacco, A., Tavecchia, G., Viola, G., Frea, S., Briani, M., Bertoldi, L. F., Bertaina, M., Potena, L., Valente, S., Marini, M., De Ferrari, G. M., D'Ettore, N., Cardinale, A., Camporotondo, R., Rota, M., Tavazzi, G., Morici, N., …, & Altshock‐2 investigators (2025). Pre-Admission Beta-Blocker Therapy and Outcomes in Cardiogenic Shock: Insights from the Altshock-2 Registry. ESC Heart Failure. https://doi.org/10.1002/ehf2.15322

Vancouver

Pagnesi M, Riccardi M, Sacco A, Tavecchia G, Viola G, Frea S, et al. Pre-Admission Beta-Blocker Therapy and Outcomes in Cardiogenic Shock: Insights from the Altshock-2 Registry. ESC Heart Failure. 2025. doi:10.1002/ehf2.15322

BibTeX
@article{Pagnesi2025,
  author = {Pagnesi, Matteo and Riccardi, Mauro and Sacco, Alice and Tavecchia, Giovanni and Viola, Giovanna and Frea, Simone and Briani, Martina and Bertoldi, Letizia Fausta and Bertaina, Maurizio and Potena, Luciano and Valente, Serafina and Marini, Marco and De Ferrari, Gaetano Maria and D'Ettore, Nicoletta and Cardinale, Astrid and Camporotondo, Rita and Rota, Matteo and Tavazzi, Guido and Morici, Nuccia and Pappalardo, Federico and Metra, Marco and Altshock‐2 investigators, Altshock‐2 investigators},
  title = {Pre-Admission Beta-Blocker Therapy and Outcomes in Cardiogenic Shock: Insights from the Altshock-2 Registry},
  journal = {ESC Heart Failure},
  year = {2025},
  doi = {10.1002/ehf2.15322}
}
Kostenlos starten →